CN112166122A - 抗体-肿瘤坏死因子α融合蛋白及其制法和应用 - Google Patents

抗体-肿瘤坏死因子α融合蛋白及其制法和应用 Download PDF

Info

Publication number
CN112166122A
CN112166122A CN201880092569.1A CN201880092569A CN112166122A CN 112166122 A CN112166122 A CN 112166122A CN 201880092569 A CN201880092569 A CN 201880092569A CN 112166122 A CN112166122 A CN 112166122A
Authority
CN
China
Prior art keywords
nucleic acid
fusion protein
tnf
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880092569.1A
Other languages
English (en)
Inventor
蔡则玲
陈羿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN112166122A publication Critical patent/CN112166122A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

文本中提供了一种抗体‑肿瘤坏死因子α融合蛋白及其制法和应用。具体而言，本文涉及一种包含抗体部分和TNFα部分的融合蛋白，其核酸编码分子、核酸构建体、宿主细胞和制备方法，以及上述物质在预防和/或治疗肿瘤中的应用。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201880092569.1A 2018-12-13 2018-12-13 抗体-肿瘤坏死因子α融合蛋白及其制法和应用 Pending CN112166122A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/120839 WO2020118605A1 (zh) 2018-12-13 2018-12-13 抗体-肿瘤坏死因子α融合蛋白及其制法和应用

Publications (1)

Publication Number Publication Date
CN112166122A true CN112166122A (zh) 2021-01-01

Family

ID=71075883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880092569.1A Pending CN112166122A (zh) 2018-12-13 2018-12-13 抗体-肿瘤坏死因子α融合蛋白及其制法和应用

Country Status (3)

Country Link
US (1) US20220098262A1 (zh)
CN (1) CN112166122A (zh)
WO (1) WO2020118605A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925929A (zh) 2021-09-22 2023-04-07 上海康岱生物医药技术股份有限公司 抗tnfr2单克隆抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223968A (ja) * 1993-12-24 1995-08-22 Merck Patent Gmbh 免疫抱合体
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
WO2003068924A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2006115800A2 (en) * 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CN103833856A (zh) * 2012-11-22 2014-06-04 上海康岱生物医药技术有限公司 抑制taci-baff复合物形成的融合蛋白及其制法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07223968A (ja) * 1993-12-24 1995-08-22 Merck Patent Gmbh 免疫抱合体
CN1374871A (zh) * 1999-07-21 2002-10-16 利思进药品公司 增强蛋白和肽抗原免疫原性的Fc融合蛋白
WO2003068924A2 (en) * 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Fusion proteins of humanized g250 specific antibodies and uses thereof
WO2006115800A2 (en) * 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CN103833856A (zh) * 2012-11-22 2014-06-04 上海康岱生物医药技术有限公司 抑制taci-baff复合物形成的融合蛋白及其制法和用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUER，S.等: "Protein TNF by an Antibody-Derived TNF Fusion Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein", vol. 172, pages 3930 - 3939 *
CHRIST，O.等: "Efficacy of Local versus Systemic Application of Antibody-Cytokine Fusion Proteins in Tumor Therapy", vol. 7, pages 985 - 998, XP055719092 *
HOOGENBOOM，H.R.等: "Construction and expression of antibody-tumor necrosis factor fusion proteins", vol. 28, no. 9, pages 1027 - 1037 *
韩骅 等: "人黑色素瘤单抗 VH TNF 融合蛋白基因的构建和表达", vol. 19, no. 1, pages 15 - 17 *

Also Published As

Publication number Publication date
US20220098262A1 (en) 2022-03-31
WO2020118605A1 (zh) 2020-06-18

Similar Documents

Publication Publication Date Title
JP7004470B2 (ja) Ｃｄ－１９を標的とするキメラ抗原受容体
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
CN105121474B (zh) 融合免疫调节蛋白及其制备方法
CN110950953B (zh) 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN108250303B (zh) 单域抗体融合蛋白及其应用
JP2019533475A (ja) 抗ｃｔｌａ４−抗ｐｄ−１二機能性抗体、その医薬組成物および使用
CN110300603B (zh) Cd47-car-t细胞
JP2020527939A (ja) タンパク質性ヘテロ二量体及びその用途
US11529425B2 (en) Immunoconjugates comprising signal regulatory protein alpha
WO2022161409A1 (zh) 双特异性cs1-bcma car-t细胞及其应用
CN113354739B (zh) 一种靶向表达Claudin18.2细胞的嵌合抗原受体及其应用
KR20190134994A (ko) Muc1 및 cd3에 결합하는 다중특이적 항체 작제물
CN116234911A (zh) 特异性结合msln的嵌合抗原受体及其应用
US20210107961A1 (en) Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
KR20160138309A (ko) Cd147에 결합하는 항체 치료제
CN113754780A (zh) 靶向cldn18.2的嵌合抗原受体、其组合物及用途
WO2023222035A1 (zh) 抗tigit抗体与il2的融合蛋白或其变体及其应用
JP2020515624A (ja) Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物
CN112166122A (zh) 抗体-肿瘤坏死因子α融合蛋白及其制法和应用
KR20160135764A (ko) 이중-특이적 항원-결합 폴리펩티드
KR20160107070A (ko) 인간 인터페론-베타 변이체가 접합된 면역사이토카인 및 이의 제조방법
CN114437218B (zh) 靶向cd276的嵌合抗原受体以及包含其的免疫细胞
WO2022100585A1 (zh) 抗Her-2抗体-趋化因子融合蛋白及其制法和应用
CN114316045A (zh) 抗pd-l1抗体及其用途
CN114685682B (zh) 一种靶向表达cldn 18.2的细胞的嵌合抗原受体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination